Results 81 to 90 of about 20,614 (289)
Frontiers in Pediatrics, 2019 Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available.
Tanja Gangnus, Bjoern B. Burckhardt
doaj +1 more source
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Journal of Cardiovascular Pharmacology and Therapeutics, 2022 Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF.
Rui Zhang MD, PhD +6 more
doaj +1 more source
What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? [PDF]
, 2017 AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF).
Clark, Andrew L. +8 more
core +3 more sources
Role of Echocardiography in Evaluation of the Effects of Sacubitril–Valsartan on Vascular Stiffness in Patients with Heart Failure: Review Article [PDF]
, 2022 Elshaimaa Ali Elsadek Seaoud +3 more
openalex +1 more source
Clinical Cardiology, 2023 Sacubitril‐valsartan (SV) monotherapy has been shown to help patients with Heart failure with reduced ejection fraction (HFrEF), but whether adding a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) improves treatment results even more is unknown.
Xingchun Mo, Pingfan Lu, Xiaojing Yang
semanticscholar +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
ESC Heart Failure, 2021 Aims Sacubitril/valsartan combines renin–angiotensin–aldosterone system inhibition with amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides exert direct effects on pulmonary vasculature.
Jeffrey S. Tran +9 more
doaj +1 more source
ESC Heart Failure, 2023 In recent years, survival in patients with breast cancer has increased. Despite the improvement in outcomes of those patients, the risk of treatment‐related cardiotoxicity remains high, and its presence has been associated with a higher risk of treatment
M. Tajstra +17 more
semanticscholar +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source
Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]
, 2019 The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core +1 more source